Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%

MT Newswires Live

06/23

Optiscan Imaging (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.

AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.

AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.

Its shares jumped 9% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545334450"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545334450\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545334450?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545334450","market":"sh","top_or_hot":-1,"title":"Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.</p><p>AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.</p><p>AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.</p><p>Its shares jumped 9% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-23 09:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.</p><p>AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.</p><p>AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.</p><p>Its shares jumped 9% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545334450","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545334450","pubTimestamp":1750643944,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Optiscan Imaging  entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.Its shares jumped 9% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","OIL.AU":"OPTISCAN IMAGING LIMITED"},"translate_title":"Optiscan Imaging与美国公司就成像造影剂应用达成合作协议，股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OIL.AU":0.9},"content_text":"Optiscan Imaging (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.Its shares jumped 9% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}